^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Cosela (trilaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
G1 THERAPEUTICS ANNOUNCES ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR TRILACICLIB FOR PATIENTS WITH SMALL CELL LUNG CANCER
Published date:
08/17/2020
Excerpt:
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for trilaciclib for small cell lung cancer (SCLC) patients being treated with chemotherapy and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2021.
